These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38609947)

  • 1. Finely tuned ionizable lipid nanoparticles for CRISPR/Cas9 ribonucleoprotein delivery and gene editing.
    Im SH; Jang M; Park JH; Chung HJ
    J Nanobiotechnology; 2024 Apr; 22(1):175. PubMed ID: 38609947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
    Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
    J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
    Li S; Song Z; Liu C; Chen XL; Han H
    ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
    Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
    Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.
    Bykonya AG; Lavrov AV; Smirnikhina SA
    Mol Biotechnol; 2023 Feb; 65(2):181-195. PubMed ID: 35322386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
    Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
    J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEG-Delivered CRISPR-Cas9 Ribonucleoproteins System for Gene-Editing Screening of Maize Protoplasts.
    Sant'Ana RRA; Caprestano CA; Nodari RO; Agapito-Tenfen SZ
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32887261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipopeptide-Based Nanosome-Mediated Delivery of Hyperaccurate CRISPR/Cas9 Ribonucleoprotein for Gene Editing.
    Thach TT; Bae DH; Kim NH; Kang ES; Lee BS; Han K; Kwak M; Choi H; Nam J; Bae T; Suh M; Hur JK; Kim YH
    Small; 2019 Nov; 15(46):e1903172. PubMed ID: 31588686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipofection-mediated genome editing using DNA-free delivery of the Cas9/gRNA ribonucleoprotein into plant cells.
    Liu W; Rudis MR; Cheplick MH; Millwood RJ; Yang JP; Ondzighi-Assoume CA; Montgomery GA; Burris KP; Mazarei M; Chesnut JD; Stewart CN
    Plant Cell Rep; 2020 Feb; 39(2):245-257. PubMed ID: 31728703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron-Confined CRISPR/Cas9-Ribonucleoprotein Delivery System for Redox-Responsive Gene Editing.
    Qiu L; Sun M; Chen L; Jiang J; Fu Z; Wang Y; Bi Y; Guo Q; Bai H; Chen S; Gao L; Chang G
    Small; 2024 Jul; 20(30):e2309431. PubMed ID: 38402425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles.
    Mazurov D; Ramadan L; Kruglova N
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.
    Bloomer H; Khirallah J; Li Y; Xu Q
    Adv Drug Deliv Rev; 2022 Feb; 181():114087. PubMed ID: 34942274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
    Suzuki Y; Onuma H; Sato R; Sato Y; Hashiba A; Maeki M; Tokeshi M; Kayesh MEH; Kohara M; Tsukiyama-Kohara K; Harashima H
    J Control Release; 2021 Feb; 330():61-71. PubMed ID: 33333121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of CRISPR-Cas12a Ribonucleoprotein Complex for Genome Editing in an Embryogenic Citrus Cell Line.
    Fang H; Culver JN; Niedz RP; Qi Y
    Methods Mol Biol; 2023; 2653():153-171. PubMed ID: 36995625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application.
    Sun B; Chen H; Gao X
    J Control Release; 2021 Sep; 337():698-717. PubMed ID: 34364918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.
    Rosenblum D; Gutkin A; Kedmi R; Ramishetti S; Veiga N; Jacobi AM; Schubert MS; Friedmann-Morvinski D; Cohen ZR; Behlke MA; Lieberman J; Peer D
    Sci Adv; 2020 Nov; 6(47):. PubMed ID: 33208369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells.
    Rouatbi N; Walters AA; Costa PM; Qin Y; Liam-Or R; Grant V; Pollard SM; Wang JT; Al-Jamal KT
    J Control Release; 2024 Nov; 375():776-787. PubMed ID: 39284526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.